Trending Now
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Says the ZENITH20 Phase 2 Clinical Trial...
The evaluation of poziotinib in the ZENITH20 Phase 2 clinical trial has accomplished the pre-specified primary endpoint. According to Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), which...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Pre-Market SPY moves up over 300
Today we are seeing a rally over the weekend in our markets as well as in the markets in Europe and in Asia....
MAKE IT MODERN
LATEST REVIEWS
Sangamo Therapeutics Inc (NASDAQ:SGMO) Inks A Collaboration Agreement With Novartis AG...
Sangamo Therapeutics Inc (NASDAQ:SGMO) entered an international licensing collaboration accord with Novartis AG (NYSE:NVS) to commercialize/ develop gene regulation therapies (GRT).
GRT targets ASD
Sangamo will...
MAKE IT MODERN
PERFORMANCE TRAINING
Oragenics, Inc (NYSE: OGEN) Surges 34% Amidst Webinar Announcement and Intranasal Pharmaceutical Development
Oragenics, Inc. (NYSE: OGEN) has recently garnered significant attention with a notable increase in its stock price. As of 3:38 PM EDT,...
Verastem, Inc. (VSTM) Sees Major Drop: Analyzing the Factors Behind the 62% Decline
Verastem, Inc. (NASDAQ: VSTM), a biopharmaceutical company focused on developing cancer treatments, recently experienced a significant drop in its stock price. According...
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Receives Study May Proceed Letter from The FDA For...
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) has announced that the US FDA has issued a Study May Proceed notice for Halo-Lido for hemorrhoids treatment. The...
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Begins a Phase 3 Study of Pitolisant
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has started a Phase 3 study to assess the safety and efficacy of pitolisant. This drug could potentially...
Sesen Bio Inc (NASDAQ:SESN) Receives Approval Of CDE Of China For Its Drug –...
Sesen Bio Inc (NASDAQ:SESN) received approval for its drug – Vicineum from the CDE of China to treat BCG unresponsive NMIBC (non-muscle invasive bladder...
MAKE IT MODERN
